Company Filing History:
2 out of 9 
2 out of 3,107 
Years Active: 2020-2022
Title: The Innovative Mind of Shuai Tang: A Pioneer in Kinase Inhibition
Introduction: Shuai Tang, an accomplished inventor based in Shanghai, China, has made significant contributions to the field of pharmaceutical innovations. With a total of two patents to his name, Tang's work primarily focuses on developing compounds that inhibit critical kinases, showcasing his dedication to addressing complex health issues related to mutations.
Latest Patents: Shuai Tang’s latest patents reflect his expertise and innovative spirit. The first patent, titled "Compound having ERK kinase inhibitory activity and use thereof," relates to a compound designed to inhibit ERK kinases, specifically ERK1 and/or ERK2 kinases. This invention not only details the compound but also outlines its preparation method and pharmaceutical applications. The second patent, "Compound having mutant IDH inhibitory activity, preparation method and use thereof," introduces a compound effective in preventing and treating diseases associated with IDH mutations. It encompasses the compound’s structural formula, various forms, and its utility in drug development aimed at these critical health issues.
Career Highlights: Shuai Tang has collaborated with notable organizations including Shanghai Haihe Pharmaceutical Co., Ltd. and the Chinese Academy of Sciences. His tenure in these institutions reflects his commitment to advancing scientific research and innovation in the pharmaceutical industry.
Collaborations: Throughout his career, Tang has worked closely with esteemed colleagues such as Meiyu Geng and Min Huang. These collaborations have provided unique opportunities for knowledge exchange and have amplified the impact of his innovative contributions.
Conclusion: With two patents under his belt, Shuai Tang exemplifies the spirit of innovation necessary to drive progress in pharmaceutical sciences. His focused research on kinase inhibition presents promising avenues for future medical therapies, ultimately contributing to the fight against diseases linked to genetic mutations.